Descrizione

The global induced pluripotent stem cells market is poised to grow by US$ 1.9 miliardi durante 2022-2028, procedendo a un CAGR di 8.6% durante il periodo di previsione, secondo la società di dati e analisi StrategyHelix.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for induced pluripotent stem cells. The global induced pluripotent stem cells market is segmented on the basis of function, reprogramming method, method, applicazione, e regione. By function, the global induced pluripotent stem cells market has been segmented into cell analysis, cell culture, cell differentiation, cellular and molecular bioengineering, cellular reprogramming. In 2021, the cell differentiation segment made up the largest share of revenue generated by the induced pluripotent stem cells market. Based upon reprogramming method, the global induced pluripotent stem cells market is categorized into integrated, non-integrated. The non-integrated segment was the largest contributor to the global induced pluripotent stem cells market in 2021. On the basis of method, the global induced pluripotent stem cells market has been segmented into DNA-based, protein-based, RNA-based, small molecule-based. The DNA-based segment is estimated to account for the largest share of the global induced pluripotent stem cells market. Per applicazione, the global induced pluripotent stem cells market has been segmented into academic research, drug development, regenerative medicine. The drug development segment held the largest share of the global induced pluripotent stem cells market in 2021 e si prevede che manterrà la sua quota durante il periodo di previsione. Geograficamente, the global induced pluripotent stem cells market is segmented into Asia Pacific, Europa, Stati Uniti d'America, Rest of the World (RoW).

The global induced pluripotent stem cells market is highly competitive. The report also includes the profiles of leading companies such as Bio-Techne Corporation, BlueRock Therapeutics LP, Bristol Myers Squibb (BMS), Cell Signaling Technology Inc., Corning Incorporated, FUJIFILM Cellular Dynamics Inc., InvivoGen Limited, Lonza Group AG, Merck KGaA, Promega Corporation, Qiagen N.V., STEMCELL Technologies Inc., Thermo Fisher Scientific Inc.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the induced pluripotent stem cells market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Function: cell analysis, cell culture, cell differentiation, cellular and molecular bioengineering, cellular reprogramming
Reprogramming method: integrated, non-integrated
Method: DNA-based, protein-based, RNA-based, small molecule-based
Applicazione: academic research, drug development, regenerative medicine
Regione: Asia Pacifico, Europa, Stati Uniti d'America, Rest of the World (RoW)
Anni considerati: la presente relazione copre il periodo 2018 A 2028

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the global induced pluripotent stem cells market
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. Induced pluripotent stem cells market overview
Parte 3. Market breakdown by function
– Cell analysis
– Cell culture
– Cell differentiation
– Cellular and molecular bioengineering
– Cellular reprogramming
Parte 4. Market breakdown by reprogramming method
– Integrated
– Non-integrated
Parte 5. Market breakdown by method
– DNA-based
– Protein-based
– RNA-based
– Small molecule-based
Parte 6. Market breakdown by application
– Academic research
– Drug development
– Regenerative medicine
Parte 7. Market breakdown by region
– Asia Pacifico
– Europa
– Stati Uniti d'America
– Rest of the World (RoW)
Parte 8. Aziende chiave
– Bio-Techne Corporation
– BlueRock Therapeutics LP
– Bristol Myers Squibb (BMS)
– Cell Signaling Technology, Inc.
– Corning Incorporated
– FUJIFILM Cellular Dynamics, Inc.
– InvivoGen Limited
– Lonza Group AG
– Merck KGaA
– Promega Corporation
– Qiagen N.V.
– STEMCELL Technologies Inc.
– Thermo Fisher Scientific Inc.
Informazioni su StrategyHelix
Disclaimer